Works matching IS 1170-7690 AND VI 43 AND IP 1 AND DT 2025
Results: 9
Acknowledgement to Referees: Acknowledgement to Referees: Acknowledgement to Referees.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 1, doi. 10.1007/s40273-024-01464-x
- Publication type:
- Article
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation: Universal Health Coverage of Opioid Agonist Treatment in Norway: P. Chaudhary et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 93, doi. 10.1007/s40273-024-01442-3
- By:
- Publication type:
- Article
Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach: Incremental Cost per QALY of the Spanish NHS: L. Vallejo-Torres et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 109, doi. 10.1007/s40273-024-01441-4
- By:
- Publication type:
- Article
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy: Traditional Versus Pharmacometric Pharmacoeconomic Models for Cost-Utility Analysis of Sunitinib: M. Centanni et al
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 31, doi. 10.1007/s40273-024-01438-z
- By:
- Publication type:
- Article
How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences: Tests of Health-Outcome Sequences: F. R. Johnson et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 45, doi. 10.1007/s40273-024-01437-0
- By:
- Publication type:
- Article
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis: A DCEA of Tocilizumab Coverage for Inpatients with COVID-19 and the Health Equity Impact in the USA: S. Kowal, K. L. Rosettie
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 67, doi. 10.1007/s40273-024-01436-1
- By:
- Publication type:
- Article
Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification: Design and Features of Pricing and Payment Schemes for Health Technologies: V. Ardito et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 5, doi. 10.1007/s40273-024-01435-2
- By:
- Publication type:
- Article
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability: Framework and Calculation Tool to Determine the Suitability of MEAs: M.H.E. Callenbach et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 53, doi. 10.1007/s40273-024-01433-4
- By:
- Publication type:
- Article
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States: Economic Burden Associated With Pulmonary Arterial Hypertension in the United States: A. Watzker et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 83, doi. 10.1007/s40273-024-01427-2
- By:
- Publication type:
- Article